IQVIA (NYSE:IQV) Downgraded by StockNews.com

IQVIA (NYSE:IQVGet Free Report) was downgraded by stock analysts at StockNews.com from a “buy” rating to a “hold” rating in a research report issued to clients and investors on Thursday.

IQV has been the topic of several other research reports. Truist Financial boosted their target price on shares of IQVIA from $240.00 to $286.00 and gave the stock a “buy” rating in a research report on Thursday, January 4th. JPMorgan Chase & Co. dropped their price objective on shares of IQVIA from $262.00 to $239.00 and set an “overweight” rating on the stock in a report on Monday, November 13th. Guggenheim dropped their price objective on shares of IQVIA from $253.00 to $220.00 and set a “buy” rating on the stock in a report on Friday, November 3rd. Evercore ISI dropped their price objective on shares of IQVIA from $260.00 to $240.00 in a report on Wednesday, October 11th. Finally, Morgan Stanley dropped their price objective on shares of IQVIA from $240.00 to $225.00 and set an “overweight” rating on the stock in a report on Friday, November 3rd. Three research analysts have rated the stock with a hold rating and nine have given a buy rating to the company’s stock. Based on data from MarketBeat, IQVIA currently has a consensus rating of “Moderate Buy” and a consensus target price of $244.31.

View Our Latest Analysis on IQV

IQVIA Stock Up 1.2 %

Shares of NYSE IQV traded up $2.66 during trading hours on Thursday, hitting $217.00. 981,342 shares of the stock were exchanged, compared to its average volume of 1,017,640. The company has a quick ratio of 0.79, a current ratio of 0.79 and a debt-to-equity ratio of 2.12. The company has a market cap of $39.60 billion, a PE ratio of 36.47, a PEG ratio of 2.46 and a beta of 1.48. The firm has a fifty day moving average price of $219.60 and a 200-day moving average price of $211.48. IQVIA has a 12 month low of $167.42 and a 12 month high of $237.96.

Insider Activity

In other news, insider Kevin C. Knightly sold 13,117 shares of the company’s stock in a transaction that occurred on Friday, December 1st. The stock was sold at an average price of $214.03, for a total value of $2,807,431.51. Following the completion of the sale, the insider now directly owns 7,347 shares in the company, valued at $1,572,478.41. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Company insiders own 1.50% of the company’s stock.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in IQV. AdvisorNet Financial Inc grew its position in IQVIA by 327.6% in the fourth quarter. AdvisorNet Financial Inc now owns 124 shares of the medical research company’s stock worth $29,000 after acquiring an additional 95 shares during the period. BKM Wealth Management LLC acquired a new position in IQVIA during the fourth quarter worth $32,000. ST Germain D J Co. Inc. acquired a new position in IQVIA during the second quarter worth $33,000. Activest Wealth Management acquired a new position in IQVIA during the fourth quarter worth $35,000. Finally, Live Oak Investment Partners acquired a new position in IQVIA during the fourth quarter worth $41,000. 86.82% of the stock is currently owned by hedge funds and other institutional investors.

About IQVIA

(Get Free Report)

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.

Featured Articles

Analyst Recommendations for IQVIA (NYSE:IQV)

Receive News & Ratings for IQVIA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IQVIA and related companies with MarketBeat.com's FREE daily email newsletter.